Market Outlook

By 2035, the U.S. IVD Reagents Market is expected to reach approximately USD 47.88 billion, expanding at a CAGR of 7.40% during the forecast period 2026–2035. The market is estimated at USD 23.45 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The U.S. IVD reagents industry represents the recurring-consumption engine of the broader in vitro dre purchased through multi-year capital cycles, reagents generate repeat revenue every time a patient specimen is processed. Clinical chemistry reagents, immunoassay kits, molecular diagnostic assay cartridges, primers and probes, antibodies, antigens, enzymes, substrates, calibrators, controls, stains, microbiology media and other assay-specific materials are consumed continuously across hosting sites.

Approximately 14 billion laboratory tests are performed in the United States each year. This enormous testing base makes reagent utilization one of the most durable recurring expenditure categories in healthcare diagnostics. Laboratory results influence a large majority of medical decisions, meaning reagent reliability, analytical sensitivity, lot consistency, calibration performance and turnaround time have direct implications for clinical workflow and treatment decisions.

The market expanded from approximately USD 19.10 billion in 2021 to USD 22.05 billion in 2024, followed by an estimated increase to USD 23.45 billion in 2025. Market composition changed considerably during this period. COVID-related molecular and antigen reagent demand declined from pandemic-era levels, but underlying utilization strengthened across routine chemistry, immunodiagnostics, oncology, sexually transmitted infections, respiratory panels, gastrointestinal testing, women’s health, cardiac biomarkers, diabetes monitoring and precision medicine.

From 2026 onward, growth is expected to become structurally broader. The market is projected to reach approximately USD 25.19 billion in 2026, USD 33.51 billion by 2030 and USD 47.88 billion by 2035. Molecular diagnostics and high-value immunoassay reagents are expected to grow faster than conventional chemistry reagents, while clinical chemistry will continue generating substantial absolute revenue because of its enormous testing frequency.

For market-sizing purposes, the U.S. IVD reagents market includes assay-specific diagnostic chemistry, kits, reagent packs, cartridges containing diagnostic chemistry, primers, probes, antibodies, antigens, enzymes, substrates, calibrators, controls, staining materials and microbiology reagents used for human in vitro diagnosis. Diagnostic instruments, standalone laboratory software, specimen-collection products and general laboratory disposables are excluded unless biochemical assay reagents form an inseparable component of the diagnostic cartridge.

A central commercial feature of this market is the installed-base business model. Diagnostic manufacturers frequently place or sell analyzers at economically competitive terms and capture long-duration revenue through proprietary reagent consumption. Consequently, competition is increasingly determined by the breadth of assay menus, reagent utilization per instrument, customer retention, automation compatibility, laboratory throughput, lot-to-lot consistency and the manufacturer’s ability to secure multi-year reagent commitments with large U.S. health systems.

 

Introduction

According to the U.S. IVD Reagents Market Report, diagnostic reagents occupy a strategically important position between clinical laboratory infrastructure and actual patient testing. An analyzer without its compatible reagent portfolio has limited economic value. The recurring reagent stream therefore determines both the lifetime economics of diagnostic systems and the operational flexibility of laboratories.

The U.S. market is supported by one of the world’s most extensive diagnostic infrastructures. More than 300,000 active or certified clinical laboratory providers operate across the country under the broader CLIA framework, ranging from high-complexity academic medical center laboratories to physician-office laboratories and waived testing sites. The United States also has approximately 6,100 hospitals, more than 907,000 staffed hospital beds and over 35 million annual hospital admissions, providing a large institutional base for continuous diagnostic consumption.

Demand is further reinforced by chronic disease prevalence. More than 40 million people in the United States are estimated to have diagnosed or undiagnosed diabetes, while more than 115 million adults have prediabetes. Chronic kidney disease affects roughly one in seven U.S. adults. These patient populations generate repeated requirements for glucose, HbA1c, renal chemistry, lipid, electrolyte, liver-function, endocrine and other routine laboratory reagents.

Oncology creates a different but increasingly high-value reagent opportunity. More than 2 million new cancer cases were expected in the United States in 2025. Cancer diagnosis and treatment increasingly involve immunohistochemistry, tumor markers, companion diagnostics, molecular profiling, circulating biomarkers, PCR, fluorescence-based assays and sequencing-related reagent workflows. Reagent revenue therefore grows not only with test volume but also with the rising complexity and value of each diagnostic episode.

Infectious disease remains another major demand pool. Despite normalization of COVID-19 testing, respiratory infections continue to support multiplex influenza, SARS-CoV-2 and RSV assays, while more than 2.2 million combined cases of chlamydia, gonorrhea and syphilis were reported nationally in 2024. Molecular STI testing, blood-borne pathogen screening, gastrointestinal panels, hospital-acquired infection testing and antimicrobial-resistance workflows create significant recurrent reagent utilization.

The U.S. market is simultaneously shifting from centralized testing toward a hub-and-spoke diagnostic model. High-complexity molecular and specialty assays remain concentrated in reference and academic laboratories, but increasingly sophisticated PCR, immunoassay and cartridge-based technologies are moving into emergency departments, urgent care centers, physician practices and other decentralized environments. Manufacturers capable of supporting both central laboratories and near-patient testing are therefore building more defensible reagent franchises.

The economics of reagent procurement are becoming equally important. Large integrated delivery networks increasingly evaluate cost per reportable result rather than reagent price per test. Parameters such as repeat-test frequency, calibration stability, quality-control requirements, analyzer downtime, technician hands-on time, reagent wastage, onboard stability and inventory expiration can materially change the actual cost of laboratory operations.

Through 2035, the strongest companies are likely to be those that combine broad testing menus, high-throughput automation, closed-loop quality control, standardized reagents, molecular innovation and flexible contracting. The market is evolving from the sale of individual reagents toward integrated diagnostic ecosystems that create long-term relationships between vendors and laboratories.

 

Key Market Drivers: What’s Fueling the U.S. IVD Reagents Market Boom?

The first structural driver is the enormous volume of laboratory testing performed in the United States. More than 14 billion tests are conducted annually. Even modest increases in per-patient testing intensity translate into substantial reagent consumption when applied across this national testing base. Chemistry panels, complete blood counts, infectious disease assays, endocrine testing, coagulation testing, cardiac biomarkers and other high-frequency procedures create recurring demand that is relatively insulated from conventional medical-device replacement cycles.

The second driver is the increasing chronic disease burden. Diabetes illustrates the scale of this opportunity. More than 40 million Americans are estimated to have diabetes, and the much larger prediabetes population creates ongoing demand for screening and monitoring. Clinical chemistry reagents for glucose, HbA1c, lipid panels, renal assessment and metabolic monitoring therefore represent durable consumption categories. Similar recurring testing requirements exist for kidney disease, thyroid disorders, cardiovascular disease and autoimmune conditions.

The third driver is the expansion of molecular diagnostics. PCR and other nucleic acid amplification methods have migrated from specialized laboratories toward mainstream clinical workflows. Molecular reagents now support respiratory infections, STIs, gastrointestinal infections, transplant monitoring, oncology, inherited disease, women’s health and antimicrobial-resistance testing. Molecular assays generally carry higher reagent value per test than traditional routine chemistry, making the segment disproportionately important to revenue growth.

The fourth driver is the commercialization of multiplex testing. Laboratories increasingly prefer assays that detect several clinically relevant targets from one specimen. Respiratory panels capable of differentiating influenza, SARS-CoV-2 and RSV represent a visible example. Gastrointestinal, meningitis, bloodstream infection and STI panels follow the same economic logic. Multiplex testing can shorten diagnostic pathways, reduce sequential testing and support faster treatment decisions, although laboratories remain sensitive to reimbursement and unnecessary panel utilization.

The fifth driver is oncology and precision medicine. The 2-million-plus annual U.S. cancer incidence creates a growing requirement for diagnostic stratification before treatment. Immunohistochemistry reagents, molecular oncology assays, companion diagnostics, genomic markers and circulating biomarkers increasingly determine whether a patient is eligible for targeted therapies. This moves diagnostic reagents closer to pharmaceutical treatment selection and raises their strategic value.

A sixth driver is decentralized and point-of-care testing. CLIA-waived and near-patient testing allows healthcare providers to obtain actionable results during the same encounter. Urgent care centers, physician offices, retail clinics and hospital emergency departments can use cartridge-based molecular or immunoassay systems without operating full central laboratories. Reagent manufacturers benefit because each instrument placement creates a recurring cartridge stream.

The seventh driver is laboratory automation and workforce economics. U.S. laboratories continue to face staffing pressure, particularly for experienced medical laboratory scientists and specialized molecular personnel. High-throughput automated platforms can reduce manual pipetting, streamline reagent loading, automate calibration and integrate quality-control processes. Reagents designed for long onboard stability, minimal preparation and random-access testing provide meaningful labor advantages.

Another important driver is the installed-base effect. Once a hospital standardizes around a major chemistry, immunoassay or molecular platform, switching suppliers can require instrument replacement, assay validation, staff retraining, IT reconfiguration and workflow disruption. This creates substantial customer retention for manufacturers with strong reagent menus. As health systems consolidate laboratories across multiple hospitals, enterprise-level standardization further increases the value of installed platforms.

Public health surveillance also supports reagent demand. Influenza, RSV, emerging respiratory pathogens, STIs, foodborne pathogens and antimicrobial resistance require sustained diagnostic capability even when individual outbreaks fluctuate. The post-pandemic market is therefore not simply declining from COVID-era testing. It is transitioning toward broader multiplex infectious-disease preparedness.

Finally, reimbursement remains fundamental. U.S. laboratories operate under intense pressure from Medicare, Medicaid and commercial payers to demonstrate medical necessity while maintaining rapid turnaround. Manufacturers that can establish clinically differentiated assays, support coding and reimbursement pathways, and demonstrate downstream savings are better positioned to sustain premium reagent pricing.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in IVD reagents is moving away from incremental chemistry optimization toward integrated improvements in analytical performance, automation, multiplexing and clinical actionability.

One important direction is highly multiplexed molecular testing. Modern reagent systems can amplify and discriminate multiple nucleic acid targets simultaneously, enabling a single specimen to answer clinically broader questions. This is particularly valuable for respiratory infections and gastrointestinal disease, where symptoms caused by different pathogens frequently overlap. The commercial opportunity lies in achieving sufficient breadth without making panels unnecessarily expensive.

Point-of-care molecular chemistry represents another major innovation area. Historically, high-quality PCR required specialist laboratories. Cartridge engineering now integrates extraction, amplification and detection chemistry into closed systems that can be operated in decentralized settings. The commercial impact is significant because assay consumption can extend beyond conventional laboratories into urgent care and community settings.

Immunoassay innovation is being driven by higher analytical sensitivity and lower detection thresholds. High-sensitivity cardiac troponin, infectious disease serology, endocrine biomarkers and oncology markers illustrate how improved reagent chemistry can change clinical pathways rather than simply replace older assays. More sensitive detection enables earlier diagnosis, more precise risk stratification and potentially faster treatment.

Reagent stability is becoming an important procurement differentiator. Laboratories increasingly value ready-to-use formats, longer shelf life, longer onboard stability, fewer calibration events and reduced waste after reagent packs are opened. These improvements may appear operational rather than clinical, but they directly influence cost per reportable result and are therefore important in U.S. value-analysis decisions.

Quality-control innovation is also accelerating. Modern platforms increasingly link reagent lot information, calibration data, control results and instrument performance into digital quality systems. Automated flagging can reduce manual review and help large laboratories manage quality across multiple sites. Reagent suppliers that provide predictable lot-to-lot performance gain a meaningful advantage because variability can force recalibration, repeat testing and workflow disruption.

Oncology is generating sophisticated reagent development around companion diagnostics, tumor-specific antibodies, molecular signatures and targeted sequencing workflows. As cancer therapies become biomarker-driven, diagnostic reagents increasingly function as gatekeepers to treatment. This creates opportunities for collaborations between diagnostic manufacturers and pharmaceutical companies.

Laboratories are also demanding open but standardized molecular chemistry. Some high-complexity laboratories want the efficiency of automation while maintaining flexibility to introduce new assays. Reagent suppliers that can support both FDA-cleared testing and specialty laboratory workflows may benefit from this need, although regulatory requirements remain a major commercial consideration.

Artificial intelligence will influence reagents indirectly. AI does not replace chemistry, but it can optimize reflex-testing strategies, identify unusual quality-control trends, predict reagent consumption and support interpretation of complex multiplex or molecular results. The likely long-term outcome is tighter integration between physical assay reagents and digital laboratory intelligence.

 

Segmentation Insights

The U.S. IVD Reagents Market is segmented on the basis of reagent type, technology, application, end user and region.

 

By Reagent Type

Antibodies and Antigens

Antibodies and antigens represent a high-value reagent category because of their extensive use in immunoassays, infectious disease testing, autoimmune diagnostics, endocrine testing, tumor-marker detection and immunohistochemistry. Competitive differentiation depends heavily on affinity, specificity, reproducibility and stability. Demand is particularly strong where clinical laboratories require high-throughput immunochemistry combined with low false-positive or false-negative rates.

Oligonucleotides, Primers and Nucleic Acid Probes

This segment is expected to record one of the fastest growth rates through 2035. Primers and probes are fundamental to PCR, real-time PCR, genotyping, infectious disease testing, molecular oncology and other nucleic-acid-based workflows. Growth is supported by expanding molecular test menus and decentralization of PCR technology. Assay-specific proprietary oligonucleotide chemistry can create strong vendor lock-in on closed molecular systems.

Enzymes, Substrates and Diagnostic Biochemicals

Enzymes, substrates and specialized biochemical components are used across molecular diagnostics, clinical chemistry, immunoassay signal generation and other analytical methods. Their commercial value is linked to sensitivity, reaction efficiency, stability and manufacturing consistency. As laboratories pursue faster assays with lower detection limits, higher-performance enzyme systems are becoming more important.

Calibrators and Controls

Calibrators and quality-control reagents represent a smaller but strategically essential segment. U.S. laboratories operate under stringent quality-management requirements, making traceability and reliable performance essential. Demand expands with the installed analyzer base and with the growing number of analytes laboratories must validate and monitor. Third-party quality-control suppliers can also gain share where laboratories seek independent verification of instrument-manufacturer performance.

Stains, Culture Media, Buffers and Other Specialty Reagents

This category supports microbiology, hematology, histopathology, cytology and specialty laboratory workflows. While many products are mature, their utilization remains stable because they are embedded in routine laboratory practice. Growth opportunities are strongest in chromogenic media, advanced staining chemistries, antimicrobial-resistance workflows and specialized reagents that improve automation.

 

By Technology

Immunoassay and Immunochemistry

Immunoassay is one of the largest reagent technology segments in the United States. It supports thyroid testing, hormones, cardiac biomarkers, fertility, infectious disease serology, tumor markers, therapeutic drug monitoring and numerous other high-volume applications. Large automated immunochemistry platforms create durable reagent pull-through because laboratories typically purchase proprietary assay packs for many years after instrument installation.

Clinical Chemistry

Clinical chemistry generates one of the largest absolute test volumes in U.S. healthcare. Glucose, electrolytes, kidney-function tests, liver-function tests, proteins, enzymes, lipid profiles and metabolic panels are performed continuously across hospitals and reference laboratories. The segment is comparatively mature, but its recurring nature provides a stable revenue foundation. Growth is increasingly associated with automation, integrated chemistry-immunoassay platforms and laboratory consolidation.

Molecular Diagnostics

Molecular diagnostics is expected to be the strongest high-growth technology category. The segment includes PCR, NAAT, genotyping and selected sequencing-related diagnostic reagent workflows. Infectious disease remains the largest volume driver, but oncology, hereditary disease, women’s health and pharmacogenomics are increasing the addressable market. Molecular reagent economics are particularly attractive because cartridge and kit revenues can be substantial relative to analyzer cost.

Hematology and Coagulation

Hematology and coagulation reagent demand is supported by complete blood counts, differential testing, anticoagulation management, thrombosis assessment, surgical care and chronic hematologic disease. Reagents include diluents, lysing solutions, stains, coagulation substrates and specialized controls. Although routine hematology is mature, advanced cellular analysis and specialized coagulation testing provide growth opportunities.

Microbiology, Cytology and Other Diagnostic Technologies

Microbiology reagents include culture media, susceptibility-testing materials, stains and biochemical identification systems. Cytology and pathology workflows use specialized staining and processing reagents. Demand is shifting toward greater automation and faster pathogen identification, while traditional culture remains necessary for many antimicrobial-susceptibility decisions.

 

By Application

Infectious Diseases

Infectious disease represents one of the most strategically important reagent applications. Respiratory viruses, STIs, gastrointestinal infections, blood-borne pathogens, hospital-acquired infections and emerging pathogens sustain broad testing demand. The post-COVID market is increasingly centered on multiplex testing rather than single-pathogen pandemic diagnostics. High-value molecular cartridges are expected to capture a growing share of revenue.

Oncology

Oncology is expected to be among the fastest-growing application segments through 2035. More than 2 million new U.S. cancer cases annually create substantial demand for tissue biomarkers, tumor markers, molecular profiling and companion diagnostics. Reagents increasingly influence therapeutic selection, making analytical accuracy commercially critical. Oncology also offers higher revenue per test than many routine laboratory categories.

Diabetes, Cardiometabolic and Endocrine Disorders

This segment produces enormous recurring testing volume. More than 40 million Americans have diabetes, while the prediabetic population exceeds 100 million. Glucose, HbA1c, renal-function tests, lipid panels, thyroid hormones and other metabolic biomarkers are repeatedly ordered during chronic disease management. Growth is slower than molecular oncology but highly dependable.

Autoimmune and Inflammatory Disorders

Autoimmune testing includes antibodies and other biomarkers used to investigate rheumatoid arthritis, lupus, inflammatory bowel disease, celiac disease and numerous systemic disorders. Increasing specialist testing and improved biomarker specificity are supporting demand. Laboratories value consolidated autoimmune panels that can reduce manual processing.

Women’s Health, Genetic Testing and Other Applications

Women’s health includes pregnancy testing, fertility hormones, prenatal screening, HPV, cervical disease, STIs and reproductive-health diagnostics. Genetic and hereditary testing is adding new reagent opportunities as sequencing and molecular methods become more clinically accessible. Neurology, transplant diagnostics and therapeutic monitoring provide additional specialty growth areas.

 

By End User

Hospital and Health-System Laboratories

Hospital laboratories represent the largest institutional end-user group. They require high-throughput chemistry, immunoassay, hematology, coagulation, microbiology and molecular reagents and typically operate around the clock. Large health systems increasingly standardize testing platforms across multiple hospitals, giving major reagent suppliers opportunities to secure multi-year enterprise contracts.

Independent and Reference Laboratories

National, regional and specialty reference laboratories process extremely high specimen volumes and are major buyers of reagents. These customers are highly sensitive to throughput, cost per reportable result, automation and supply reliability. Their scale gives them substantial purchasing leverage, but winning a national reference-laboratory contract can generate considerable reagent volume.

Physician-Office Laboratories, Urgent Care and Clinics

This segment benefits from simplified and CLIA-waived testing. Primary-care practices, specialty clinics and urgent care centers increasingly use compact immunoassay, chemistry and molecular systems for tests that can influence immediate treatment. Reagent cartridges designed for minimal hands-on processing are particularly attractive.

Decentralized, Retail and Near-Patient Testing Sites

Retail health, pharmacy-based testing, community testing programs and other decentralized sites represent an emerging channel. Growth depends on regulatory classification, reimbursement, operator simplicity and connectivity. Molecular STI and respiratory testing are among the most commercially promising areas.

Blood Banks, Public Health Laboratories and Specialty Institutions

Blood screening, transplant testing, public health surveillance and specialty laboratory networks generate demand for highly regulated and sensitive reagents. These customers often prioritize sensitivity, traceability and supply continuity above acquisition price because diagnostic failure can have significant clinical consequences.

 

Regional Insights: Where the Market Is Growing Fastest

The South is estimated to represent the largest regional market in 2025, while the West is expected to generate the fastest percentage growth through 2035. The Northeast remains the country’s most research-intensive and specialty-testing-oriented market, while the Midwest provides substantial recurring demand from mature hospital, health-system and reference-laboratory networks.

South

The South accounted for an estimated USD 8.44 billion in 2025, equivalent to approximately 36% of the national market. It is projected to reach around USD 16.76 billion by 2035, representing an approximate 7.1% regional CAGR.

Texas is the largest Southern opportunity because of its population scale, extensive hospital infrastructure, cancer centers, infectious disease testing demand and strong laboratory presence in Houston, Dallas-Fort Worth, Austin and San Antonio. Large integrated health systems support high-throughput chemistry and immunodiagnostics, while the state’s growing metropolitan markets support decentralized molecular testing.

Florida is another major reagent market because of its large and aging population. Routine chemistry, endocrine testing, cardiac biomarkers, oncology testing and infectious disease diagnostics generate substantial recurring demand. Medicare-heavy patient volumes also make laboratory efficiency and reimbursement alignment particularly important.

North Carolina combines expanding population centers with a strong life-sciences ecosystem. Research Triangle institutions support molecular and genomic innovation, while large hospital systems create demand across conventional and specialty reagent categories. Georgia has a similarly important healthcare hub in Atlanta, with substantial hospital, public-health and reference-testing capacity.

Virginia and Maryland benefit from sophisticated health systems and proximity to federal research, public-health and biomedical institutions. Maryland has a particularly strong biotechnology ecosystem, while Virginia’s population growth supports increasing clinical testing demand. The District of Columbia, although not a state, is commercially relevant because of its concentration of academic hospitals and federal health institutions.

Tennessee is important because of Nashville’s extensive healthcare-services ecosystem and major provider organizations. Kentucky and West Virginia generate strong routine diagnostic demand associated with chronic disease burden, although laboratory access is less concentrated than in major metropolitan markets.

South Carolina is benefiting from population growth and hospital expansion along major urban and coastal corridors. Alabama and Mississippi maintain significant demand for diabetes, cardiometabolic and renal diagnostics because of elevated chronic disease prevalence. Their rural populations also make decentralized testing particularly relevant.

Louisiana combines high chronic disease burden with major clinical centers in New Orleans and Baton Rouge. Arkansas is a smaller market but provides stable chemistry and infectious-disease reagent demand through regional hospital networks. Oklahoma similarly combines metropolitan testing centers with rural areas where simplified point-of-care platforms can improve diagnostic access.

Delaware is smaller in absolute revenue but benefits from proximity to major Mid-Atlantic healthcare markets and life-sciences activity. Overall, the Southern market benefits from population growth, chronic disease prevalence and continued expansion of large health systems.

West

The West represented an estimated USD 5.28 billion in 2025 and is projected to reach approximately USD 11.97 billion by 2035, corresponding to an estimated regional CAGR of about 8.5%, the fastest among the four U.S. regions.

California is the dominant Western state market. Its scale is reinforced by major academic medical centers, biotechnology clusters, oncology programs, genomics companies and sophisticated reference laboratories. California is particularly important for early adoption of molecular oncology, companion diagnostics, sequencing-related reagents and high-complexity specialty testing.

Washington combines major integrated health systems with a strong biotechnology and research environment centered around Seattle. The state is attractive for molecular diagnostics and advanced laboratory automation. Oregon is smaller but has a sophisticated provider base and strong adoption of integrated healthcare delivery models.

Arizona is one of the fastest-growing state opportunities because of population expansion, older demographics and increasing hospital capacity in Phoenix and surrounding markets. Nevada also benefits from rapid population growth, although laboratory infrastructure is more concentrated around Las Vegas and Reno.

Colorado has a strong academic and integrated health-system environment, supporting both routine reagent consumption and advanced molecular testing. Utah combines high population growth with a prominent genetics and precision-medicine ecosystem, making it strategically important for molecular and hereditary testing.

New Mexico’s large rural population increases the relevance of decentralized testing, while urban laboratories in Albuquerque provide the main high-complexity testing base. Idaho is experiencing rapid population growth, increasing demand for hospital and physician-office diagnostics.

Montana and Wyoming are smaller reagent markets but illustrate the importance of near-patient diagnostics in sparsely populated states. Regional referral laboratories, point-of-care systems and reliable reagent distribution are particularly important because patients may be located far from tertiary medical centers.

Alaska presents unique logistics challenges that increase the value of shelf-stable, easy-to-use diagnostic reagents and decentralized testing. Hawaii similarly requires resilient supply chains because of geographic isolation, while its aging population supports routine chronic disease diagnostics.

The Western market’s long-term advantage comes from its combination of population growth and technology adoption. Manufacturers launching advanced molecular, genomic, digital pathology or precision-diagnostic solutions frequently target West Coast institutions as early clinical adopters.

Northeast

The Northeast accounted for an estimated USD 5.75 billion in 2025 and is projected to reach approximately USD 11.01 billion by 2035, representing an approximate 6.7% CAGR.

New York is the region’s largest state market. New York City contains a dense concentration of hospital laboratories, academic medical centers, specialty cancer programs and reference-testing activity. The state’s regulatory environment can create additional operational requirements, but its large test volume makes it essential for reagent manufacturers.

Massachusetts is disproportionately important relative to its population because of the Boston biotechnology, pharmaceutical and academic ecosystem. Advanced oncology, molecular diagnostics, immunodiagnostics and companion diagnostic development are especially important. Leading academic institutions often participate in validation and early adoption of new assays.

Pennsylvania combines large health systems in Philadelphia, Pittsburgh and other metropolitan areas with substantial community hospital infrastructure. It provides strong demand for chemistry, immunoassay, hematology, oncology and infectious-disease reagents.

New Jersey benefits from pharmaceutical and life-sciences activity as well as dense healthcare utilization. Companion diagnostics and specialized immunoassays are particularly relevant because of the state’s pharmaceutical-industry presence.

Connecticut maintains sophisticated health systems and laboratory networks linked to the broader New York and New England markets. Rhode Island is smaller but has concentrated academic and hospital testing demand. New Hampshire and Maine provide stable hospital laboratory utilization with increasing relevance for decentralized diagnostics outside major urban centers.

Vermont is the smallest regional state market but remains commercially important for suppliers serving integrated New England laboratory networks. Overall, the Northeast is characterized by high-complexity testing, specialist physician density and rigorous evidence requirements.

Midwest

The Midwest represented approximately USD 3.98 billion in 2025 and is expected to reach around USD 8.14 billion by 2035, corresponding to an approximate 7.4% CAGR.

Illinois is the largest Midwest reagent market, supported by Chicago’s major health systems, academic institutions and reference laboratories. High-throughput core laboratory testing generates substantial chemistry and immunoassay demand, while major tertiary centers support advanced molecular diagnostics.

Ohio has an extensive hospital and specialty-care infrastructure. Large healthcare systems create significant reagent purchasing power and frequently standardize diagnostic platforms across multiple facilities. Oncology, cardiovascular testing and routine chemistry are major demand categories.

Michigan has a substantial hospital and integrated delivery network base, supporting durable core-laboratory consumption. Minnesota is strategically important because of its medtech heritage, sophisticated healthcare institutions and strong laboratory expertise.

Indiana benefits from large health systems and central geographic positioning. Wisconsin provides stable demand from academic and community hospitals, particularly around Milwaukee and Madison. Missouri has large healthcare hubs in St. Louis and Kansas City, supporting both conventional laboratory testing and specialty diagnostics.

Iowa, Kansas and Nebraska provide significant agricultural and rural populations alongside regional referral centers. Point-of-care testing and hub-and-spoke laboratory networks are particularly important outside major metropolitan areas.

North Dakota and South Dakota are smaller state markets but have strong requirements for decentralized diagnostics, reliable reagent distribution and regional referral testing. Their dispersed populations make rapid local testing economically important even where absolute reagent volumes are lower.

The Midwest is expected to remain a dependable market for reagent manufacturers. Growth is less dependent on premium early adoption than in California or Massachusetts and more closely tied to operational reliability, health-system contracting, standardization and long-term service relationships.

 

Key Market Players

The U.S. IVD reagents competitive landscape is moderately consolidated in high-volume core laboratory categories but remains fragmented across specialty molecular, microbiology, quality-control and research-to-clinical reagent markets.

Major competitors include Roche Diagnostics; Abbott; Siemens Healthineers; Beckman Coulter Diagnostics, a Danaher company; Cepheid, a Danaher company; Thermo Fisher Scientific; bioMérieux; Bio-Rad Laboratories; QuidelOrtho; Hologic; Becton, Dickinson and Company; QIAGEN; DiaSorin; Sysmex America; Werfen; Grifols Diagnostic Solutions; Agilent Technologies; Revvity; Fujirebio Diagnostics; Sekisui Diagnostics; Meridian Bioscience; Randox Laboratories; Bio-Techne; and Illumina.

Roche, Abbott, Siemens Healthineers and Beckman Coulter are especially powerful in core laboratory chemistry and immunodiagnostics because they combine extensive analyzer installations with broad proprietary reagent menus. Their competitive advantage comes from installed-base scale, automation, enterprise contracting, service infrastructure and the ability to consolidate large numbers of assays onto standardized platforms.

Cepheid, bioMérieux, Hologic and QIAGEN are strategically important in molecular and infectious disease testing. Their growth is supported by PCR adoption, multiplex testing and increased demand for faster diagnosis. Cepheid’s cartridge-driven installed-base model illustrates the commercial attractiveness of closed molecular systems where every test generates recurring consumable revenue.

QuidelOrtho participates across immunodiagnostics, clinical chemistry and rapid testing. Bio-Rad has important positions in quality control, immunoassays, molecular diagnostics and blood testing. BD is a major competitor in microbiology and infectious disease workflows as well as selected molecular categories.

DiaSorin and Fujirebio compete strongly in specialty immunodiagnostics. Sysmex is important in hematology, while Werfen has a major presence in coagulation and specialty diagnostic categories. Grifols maintains significant blood-screening and transfusion-related diagnostic capability.

Thermo Fisher Scientific, Agilent, Revvity and Bio-Techne are influential where research, translational science and clinical diagnostics intersect. Their reagent and biomarker technologies can move from discovery workflows into clinical applications as new diagnostic targets mature.

Competition through 2035 will increasingly be platform-based. Manufacturers with broad menus can use reagent bundling and enterprise contracting to defend installed bases. Specialized competitors can still gain share by introducing assays that provide substantially faster results, better sensitivity, clinically meaningful multiplexing or access to previously underserved testing settings.

 

Recent Developments

Recent developments in the U.S. IVD reagents industry show that the market is moving toward decentralized molecular testing, broader multiplex panels and automated high-throughput core laboratories.

In January 2025, Roche received FDA clearance and a CLIA waiver for cobas liat molecular STI assay panels. The tests use PCR and are designed to produce results in approximately 20 minutes, illustrating the movement of sophisticated molecular chemistry from centralized laboratories into point-of-care environments. This development is strategically important because STI testing is traditionally associated with delayed centralized results, which can complicate treatment and follow-up.

In September 2025, Hologic received FDA 510(k) clearance for Panther Fusion gastrointestinal bacterial and expanded bacterial assays. These assays strengthen the role of automated multiplex molecular testing in gastrointestinal disease and demonstrate how established high-throughput platforms can add new reagent revenue without requiring customers to replace the installed analyzer.

Core laboratory innovation is advancing simultaneously. In March 2026, Roche received U.S. FDA clearance for new cobas analytical units designed for higher testing capacity and automation. The cobas c 703 is designed for throughput of up to approximately 2,000 tests per hour with as many as 70 reagent positions, illustrating how manufacturers are increasing reagent-menu density and laboratory throughput within existing automation ecosystems.

Respiratory testing is also evolving from COVID-centric testing toward multipathogen diagnosis. Influenza, SARS-CoV-2 and RSV can present with similar symptoms, and multiplex molecular tests increasingly allow clinicians to distinguish among them from a single specimen. This creates more sustainable long-term reagent demand than single-pathogen emergency testing.

The regulatory environment for laboratory-developed testing changed materially after the FDA’s 2024 LDT final rule was challenged. A federal district court vacated the final rule in March 2025, and the FDA subsequently reverted the relevant regulatory text in September 2025. This reduces some of the immediate regulatory assumptions that had been expected to accelerate migration from laboratory-developed assays toward commercially manufactured reagent kits. Nevertheless, laboratories and health systems remain highly focused on analytical validation, quality systems and reproducibility.

The competitive market is also moving toward assay-menu expansion rather than instrument differentiation alone. Once laboratories have invested in automation platforms, every additional FDA-cleared assay can increase utilization of existing instruments and strengthen vendor retention. Manufacturers are therefore prioritizing menu density in infectious disease, cardiac markers, oncology, endocrine testing and specialty immunoassays.

Supply-chain resilience remains strategically important. The pandemic demonstrated the operational risk associated with concentrated reagent manufacturing, raw material shortages and transportation disruption. U.S. hospital systems increasingly assess suppliers on continuity planning, domestic inventory availability, back-order frequency and alternative sourcing as well as price.

Over the forecast period, product development is expected to concentrate on multiplex molecular panels, point-of-care PCR, high-sensitivity immunoassays, oncology biomarkers, companion diagnostics, automation-compatible reagent packs and quality-control systems that reduce laboratory labor requirements.

 

Conclusion

The U.S. IVD Reagents Market Size & Share is positioned for sustained expansion from approximately USD 23.45 billion in 2025 to USD 47.88 billion by 2035, representing a 7.40% CAGR during 2026–2035.

The economic strength of the market comes from recurring consumption rather than capital-equipment purchasing. Every chemistry panel, immunoassay, molecular PCR test, hematology analysis, coagulation assay and microbiology procedure requires assay-specific materials. With more than 14 billion laboratory tests performed each year in the United States, even mature reagent categories possess a substantial recurring revenue base.

Clinical chemistry and immunoassay will continue contributing the largest absolute revenue pools because of their broad use in chronic disease management and routine hospital care. Molecular diagnostics, however, is expected to generate a disproportionate share of incremental market growth because of higher revenue per test, expanding multiplex menus, point-of-care migration and increasing use in oncology and precision medicine.

Infectious disease will remain commercially important even after COVID-19 normalization. Respiratory multiplexing, STI testing, gastrointestinal panels, antimicrobial resistance and hospital-acquired infection diagnostics create diverse demand. Oncology will be one of the strongest premium-growth applications as more therapeutic decisions depend on molecular and protein biomarkers.

Hospital and health-system laboratories will remain the dominant institutional end users, but decentralized testing will capture a growing share of incremental reagent consumption. The ability to deliver PCR-quality or laboratory-quality results in urgent care, physician offices and other near-patient settings expands the number of locations capable of generating reagent revenue.

Regional opportunity will continue to differ significantly. The South is expected to remain the largest market, rising from approximately USD 8.44 billion in 2025 to USD 16.76 billion by 2035. The West is expected to grow fastest, increasing from approximately USD 5.28 billion to USD 11.97 billion. The Northeast is expected to advance from USD 5.75 billion to USD 11.01 billion, supported by its research-intensive and high-complexity testing environment, while the Midwest is projected to increase from USD 3.98 billion to USD 8.14 billion, underpinned by large integrated provider networks and stable core laboratory testing demand.

California, Texas, Florida, New York, Pennsylvania, Massachusetts, Illinois, Ohio, North Carolina, New Jersey, Washington, Georgia, Michigan, Arizona and Minnesota will be particularly important commercial markets because of their population scale, hospital infrastructure, diagnostic testing volumes, research ecosystems or concentration of specialty care.

For reagent manufacturers, however, market attractiveness cannot be assessed by test volume alone. Future competitive advantage will depend on the lifetime economics of the diagnostic platform. A reagent portfolio that reduces calibration frequency, minimizes waste, supports longer onboard stability, expands the number of assays per analyzer, improves turnaround time and lowers laboratory labor requirements can create more value than an isolated reduction in reagent price.

Hospital procurement will therefore increasingly evaluate manufacturers through cost per reportable result, workflow resilience and enterprise standardization. Laboratories dealing with workforce constraints will favor reagents that require less preparation and manual intervention. Health systems operating multiple hospitals will favor vendors capable of standardizing assays and quality controls across an entire network.

For established IVD companies, the most defensible strategy is to expand reagent menus around existing analyzer placements and protect customer retention through automation, service quality and contracting. For emerging companies, the strongest entry opportunities are likely to exist in areas where current testing is too slow, insufficiently sensitive, operationally difficult or poorly suited to decentralized care.

The next decade of the U.S. IVD reagents industry will therefore be defined by the convergence of recurring test volume, molecular diagnostics, precision oncology, decentralized testing and laboratory workflow economics. Companies that can combine analytically differentiated chemistry with scalable manufacturing, reliable supply, reimbursement viability and measurable laboratory productivity gains will be best positioned to capture value through 2035.

 

TABLE OF CONTENT

1. U.S. IVD Reagents Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Reagent and Diagnostic Assay Manufacturers
1.6.2. Antibody, Antigen, Enzyme, Oligonucleotide and Raw Material Suppliers
1.6.3. Hospital Systems and Integrated Delivery Networks
1.6.4. Independent and Reference Laboratories
1.6.5. Physician-Office, Urgent Care and Point-of-Care Testing Providers
1.6.6. Group Purchasing Organizations, Laboratory Distributors and Channel Partners
1.6.7. Payers, FDA, CMS, CLIA Authorities and Clinical Decision-Makers
What this section provides: This section defines the U.S. IVD reagents market boundary, study scope, methodology, assumptions and stakeholder ecosystem, enabling clients to understand how reagent revenues, recurring assay consumption and market forecasts are measured and validated.

2. U.S. IVD Reagents Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.7.1. Molecular Diagnostic Reagents
2.7.2. Multiplex Infectious Disease Assays
2.7.3. Oncology and Companion Diagnostic Reagents
2.7.4. High-Sensitivity Immunoassay Reagents
2.7.5. Point-of-Care and Decentralized Molecular Testing
What this section provides: This section gives decision-makers a concise view of market size, historical development, forecast growth, reagent consumption trends, competitive intensity and priority opportunity areas through 2035.

3. U.S. IVD Reagents Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. High Volume of Clinical Laboratory Testing in the U.S.
3.1.2. Rising Chronic Disease and Routine Diagnostic Testing Burden
3.1.3. Expansion of Molecular Diagnostics and PCR-Based Testing
3.1.4. Growing Oncology and Precision Medicine Testing Requirements
3.1.5. Expansion of Decentralized and Point-of-Care Diagnostics
3.1.6. Laboratory Automation and Medical Laboratory Workforce Constraints
3.2. Restraints and Their Impact Analysis
3.2.1. Clinical Laboratory Reimbursement and Pricing Pressure
3.2.2. High Validation and Regulatory Compliance Requirements
3.2.3. Reagent Lot-to-Lot Variability and Quality-Control Risk
3.2.4. Raw Material and Diagnostic Supply Chain Dependence
3.2.5. Laboratory Budget Constraints and Vendor Consolidation
3.3. Opportunities and Their Impact Analysis
3.3.1. Multiplex and Syndromic Molecular Testing
3.3.2. Oncology Biomarkers and Companion Diagnostics
3.3.3. CLIA-Waived and Near-Patient Molecular Testing
3.3.4. High-Sensitivity and Specialty Immunoassays
3.3.5. Automated Reagent Management and Quality-Control Solutions
3.3.6. Women’s Health, Genetic and Specialty Diagnostic Testing
3.4. Challenges and Their Impact Analysis
3.4.1. Reimbursement Compression and Test Utilization Management
3.4.2. Maintaining Analytical Performance Across Large Laboratory Networks
3.4.3. Laboratory Staffing and Technical Skill Shortages
3.4.4. Managing Reagent Shelf Life, Wastage and Inventory Complexity
3.4.5. Competition Between Closed and Open Diagnostic Platforms
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Laboratory Workflow Economics Analysis
3.7. Reagent Cost-per-Reportable-Result Analysis
3.8. Hospital and Reference Laboratory Procurement Behavior Analysis
3.9. Analyzer Installed-Base and Reagent Pull-Through Economics
What this section provides: This section explains the clinical, economic, regulatory, reimbursement and laboratory-operational forces shaping U.S. IVD reagent consumption, helping clients evaluate growth opportunities, adoption barriers and execution risks.

4. U.S. IVD Reagents Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Diagnostic Laboratories and Health Systems
4.2.3. Bargaining Power of Reagent Raw Material Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Reagent Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Biological and Chemical Raw Material Sourcing
4.4.2. Antibody and Antigen Production
4.4.3. Enzyme and Oligonucleotide Manufacturing
4.4.4. Reagent Formulation and Assay Development
4.4.5. Filling, Packaging and Quality Control
4.4.6. Distribution to Clinical Laboratories and Testing Sites
4.5. Impact of Digitalization and Clinical Laboratory Automation
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework for In Vitro Diagnostic Reagents
4.8. CLIA Testing Complexity and Laboratory Compliance Landscape
4.9. Laboratory-Developed Test Regulatory Landscape
4.10. CMS Clinical Laboratory Reimbursement and Coverage Landscape
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Initiatives and Public Health Testing Programs
4.13. Impact of Escalating Geopolitical and Supply Chain Tensions
4.14. Laboratory Value Analysis and Vendor Selection Framework
4.15. Reagent-Rental and Analyzer Placement Business Model Analysis
What this section provides: This section provides a comprehensive view of the external market environment, including FDA regulation, CLIA requirements, reimbursement, laboratory automation, reagent pricing, supply-chain exposure and procurement economics.

5. U.S. IVD Reagents Market – By Reagent Type

5.1. Overview
5.1.1. Segment Share Analysis, By Reagent Type, 2025 & 2035 (%)
5.1.2. Antibodies and Antigens
5.1.2.1. Monoclonal Antibodies
5.1.2.2. Polyclonal Antibodies
5.1.2.3. Recombinant Antigens
5.1.2.4. Native Antigens
5.1.3. Oligonucleotides, Primers and Nucleic Acid Probes
5.1.3.1. PCR Primers
5.1.3.2. Fluorescent and Molecular Probes
5.1.3.3. Genotyping Oligonucleotides
5.1.3.4. Sequencing and Specialty Molecular Reagents
5.1.4. Enzymes, Substrates and Diagnostic Biochemicals
5.1.4.1. Polymerases and Reverse Transcriptases
5.1.4.2. Diagnostic Enzymes
5.1.4.3. Immunoassay Substrates
5.1.4.4. Specialty Biochemical Reagents
5.1.5. Calibrators and Controls
5.1.5.1. Assay Calibrators
5.1.5.2. Instrument-Specific Controls
5.1.5.3. Third-Party Quality Controls
5.1.5.4. Molecular and Specialty Controls
5.1.6. Stains, Culture Media, Buffers and Other Specialty Reagents
5.1.6.1. Microbiology Culture Media
5.1.6.2. Histology and Cytology Stains
5.1.6.3. Buffers and Dilution Reagents
5.1.6.4. Hematology Reagents
5.1.6.5. Other Specialty Diagnostic Reagents
What this section provides: This section identifies the reagent categories expected to generate the highest revenue contribution, recurring utilization and growth, while highlighting the shift toward molecular, specialty immunodiagnostic and quality-control reagents.

6. U.S. IVD Reagents Market – By Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
6.1.2. Immunoassay and Immunochemistry
6.1.2.1. Chemiluminescence Immunoassay
6.1.2.2. Enzyme-Linked Immunosorbent Assay
6.1.2.3. Fluorescence Immunoassay
6.1.2.4. Rapid Immunochromatographic Assays
6.1.2.5. Other Immunodiagnostic Technologies
6.1.3. Clinical Chemistry
6.1.3.1. Routine Chemistry
6.1.3.2. Electrolyte Testing
6.1.3.3. Enzyme and Protein Testing
6.1.3.4. Specialty Chemistry
6.1.4. Molecular Diagnostics
6.1.4.1. Polymerase Chain Reaction
6.1.4.2. Real-Time PCR
6.1.4.3. Other Nucleic Acid Amplification Tests
6.1.4.4. Genotyping and Mutation Testing
6.1.4.5. Sequencing-Based Diagnostic Reagents
6.1.5. Hematology and Coagulation
6.1.5.1. Hematology Reagents
6.1.5.2. Coagulation Reagents
6.1.5.3. Hemostasis and Thrombosis Assays
6.1.5.4. Specialized Cellular Analysis
6.1.6. Microbiology, Cytology and Other Diagnostic Technologies
6.1.6.1. Culture-Based Microbiology
6.1.6.2. Antimicrobial Susceptibility Testing
6.1.6.3. Cytology and Histopathology
6.1.6.4. Flow Cytometry and Specialty Testing
What this section provides: This section evaluates the principal diagnostic technologies driving reagent utilization, highlighting high-volume clinical chemistry and immunoassays alongside faster-growing molecular and specialty diagnostic platforms.

7. U.S. IVD Reagents Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Infectious Diseases
7.1.2.1. Respiratory Infections
7.1.2.2. Sexually Transmitted Infections
7.1.2.3. Gastrointestinal Infections
7.1.2.4. Blood-Borne Infectious Diseases
7.1.2.5. Hospital-Acquired Infections
7.1.2.6. Antimicrobial Resistance Testing
7.1.3. Oncology
7.1.3.1. Tumor Marker Testing
7.1.3.2. Molecular Oncology
7.1.3.3. Immunohistochemistry
7.1.3.4. Companion Diagnostics
7.1.3.5. Hereditary Cancer Testing
7.1.4. Diabetes, Cardiometabolic and Endocrine Disorders
7.1.4.1. Diabetes Testing
7.1.4.2. Lipid and Cardiometabolic Testing
7.1.4.3. Renal Function Testing
7.1.4.4. Liver Function Testing
7.1.4.5. Thyroid and Endocrine Testing
7.1.4.6. Cardiac Biomarker Testing
7.1.5. Autoimmune and Inflammatory Disorders
7.1.5.1. Rheumatoid and Connective Tissue Disorders
7.1.5.2. Gastrointestinal Autoimmune Disorders
7.1.5.3. Systemic Autoimmune Disease
7.1.5.4. Allergy and Inflammatory Biomarkers
7.1.6. Women’s Health, Genetic and Other Specialty Applications
7.1.6.1. Pregnancy and Fertility Testing
7.1.6.2. Prenatal and Reproductive Screening
7.1.6.3. HPV and Cervical Disease Testing
7.1.6.4. Genetic and Hereditary Disease Testing
7.1.6.5. Transplant Diagnostics
7.1.6.6. Neurology and Other Specialty Applications
What this section provides: This section helps clients identify clinical applications generating the strongest reagent demand, with emphasis on infectious disease, cancer diagnostics, chronic disease monitoring and emerging precision-diagnostic applications.

8. U.S. IVD Reagents Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals and Health-System Laboratories
8.1.2.1. Academic Medical Center Laboratories
8.1.2.2. Community Hospital Laboratories
8.1.2.3. Integrated Health-System Core Laboratories
8.1.2.4. Emergency and Acute-Care Testing Laboratories
8.1.3. Independent and Reference Laboratories
8.1.3.1. National Reference Laboratories
8.1.3.2. Regional Reference Laboratories
8.1.3.3. Specialty Molecular and Genetic Laboratories
8.1.3.4. Pathology and Oncology Laboratories
8.1.4. Physician-Office Laboratories, Urgent Care and Clinics
8.1.4.1. Primary-Care Physician Offices
8.1.4.2. Specialty Physician Practices
8.1.4.3. Urgent Care Centers
8.1.4.4. Community Clinics
8.1.5. Decentralized, Retail and Near-Patient Testing Sites
8.1.5.1. Retail Health Clinics
8.1.5.2. Pharmacy-Based Testing
8.1.5.3. Community Testing Programs
8.1.5.4. Other CLIA-Waived Testing Locations
8.1.6. Blood Banks, Public Health Laboratories and Specialty Institutions
8.1.6.1. Blood Banks and Transfusion Centers
8.1.6.2. Public Health Laboratories
8.1.6.3. Transplant Centers
8.1.6.4. Specialty Diagnostic Institutions
What this section provides: This section explains which U.S. laboratory settings and customer groups generate reagent consumption, how purchasing priorities differ by testing environment and where decentralized diagnostics are creating new commercial opportunities.

9. U.S. IVD Reagents Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Manufacturer-to-Laboratory Procurement
9.1.2.1. Reagent Purchase Agreements
9.1.2.2. Analyzer-Linked Reagent Contracts
9.1.2.3. Reagent-Rental Agreements
9.1.3. Integrated Delivery Network and Health-System Enterprise Contracts
9.1.3.1. Multi-Hospital Standardization Contracts
9.1.3.2. Core Laboratory Consolidation Agreements
9.1.3.3. Enterprise Diagnostic Platform Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.4.1. National GPO Agreements
9.1.4.2. Regional Purchasing Agreements
9.1.4.3. Aggregated Laboratory Procurement
9.1.5. Distributor and Specialty Laboratory Supplier Sales
9.1.5.1. National Laboratory Distributors
9.1.5.2. Specialty Diagnostic Distributors
9.1.5.3. Regional Distribution Networks
9.1.6. Physician-Office, Point-of-Care and Decentralized Procurement
9.1.6.1. Direct Point-of-Care Procurement
9.1.6.2. Distributor-Led Physician Office Sales
9.1.6.3. Retail and Community Testing Procurement
What this section provides: This section explains how IVD reagents are purchased across the U.S., including reagent-rental economics, IDN standardization, GPO influence, distributor channels and decentralized testing procurement.

10. U.S. IVD Reagents Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Clinical Laboratory and Testing Volume Analysis
10.1.4. Regional Disease Burden and Diagnostic Demand Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Molecular and Point-of-Care Testing Adoption
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Reagent Key Manufacturers, Laboratories and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region IVD Reagent Key Manufacturers, Laboratories and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Reagent Key Manufacturers, Laboratories and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Reagent Key Manufacturers, Laboratories and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Reagent Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers detailed four-region and 50-state analysis, helping clients identify diagnostic-testing hubs, laboratory infrastructure concentration, high-growth molecular testing markets and state-level commercial opportunities for IVD reagent suppliers.

11. U.S. IVD Reagents Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging and Specialty Players
11.3. Company Profiles
11.3.1. Roche Diagnostics
11.3.2. Abbott
11.3.3. Siemens Healthineers
11.3.4. Beckman Coulter Diagnostics
11.3.5. Cepheid
11.3.6. Thermo Fisher Scientific
11.3.7. bioMérieux
11.3.8. Bio-Rad Laboratories
11.3.9. QuidelOrtho
11.3.10. Hologic
11.3.11. Becton, Dickinson and Company
11.3.12. QIAGEN
11.3.13. DiaSorin
11.3.14. Sysmex America
11.3.15. Werfen
11.3.16. Grifols Diagnostic Solutions
11.3.17. Agilent Technologies
11.3.18. Revvity
11.3.19. Fujirebio Diagnostics
11.3.20. Sekisui Diagnostics
11.3.21. Meridian Bioscience
11.3.22. Randox Laboratories
11.3.23. Bio-Techne
11.3.24. Illumina
11.3.25. Mindray
Note: Each company profile will include company overview, U.S. IVD reagent portfolio, major diagnostic technologies, installed-base strategy, assay-menu positioning, U.S. market strategy, regulatory updates, product launches, partnerships, acquisitions and recent developments.
What this section provides: This section gives clients competitor benchmarking, market-share visibility, reagent portfolio positioning, installed-base economics, assay-menu strategy and strategic intelligence on major companies competing in the U.S. IVD reagents industry.

12. U.S. IVD Reagents Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multiplex and Syndromic Molecular Assays
12.2.2. Point-of-Care PCR and Decentralized Molecular Testing
12.2.3. High-Sensitivity and Next-Generation Immunoassays
12.2.4. Oncology Biomarkers and Companion Diagnostics
12.2.5. Sequencing-Enabled Clinical Diagnostics
12.2.6. AI-Assisted Laboratory Workflow and Quality Management
12.2.7. Automated Reagent Inventory and Consumption Management
12.3. Emerging Business Trends
12.3.1. Analyzer Placement and Reagent Pull-Through Models
12.3.2. Laboratory Consolidation and Enterprise Standardization
12.3.3. Expansion of CLIA-Waived Testing
12.3.4. Shift Toward Multiplex and High-Value Specialty Assays
12.3.5. Domestic Supply Chain Resilience and Manufacturing Localization
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. High-Growth Reagent Opportunity Mapping
12.7. Technology Adoption Roadmap, 2026–2035
What this section provides: This section prepares clients for future diagnostic technology shifts, evolving laboratory economics, decentralized testing, molecular innovation, investment opportunities and alternative market adoption scenarios through 2035.

13. U.S. IVD Reagents Market: Strategic Recommendations

13.1. Recommendations for IVD Reagent and Diagnostic Manufacturers
13.2. Recommendations for Hospitals, Health Systems and Clinical Laboratories
13.3. Recommendations for Independent and Reference Laboratories
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Diagnostic Startups
13.7. Go-to-Market Strategy Considerations
13.8. Assay Menu and Portfolio Expansion Guidance
13.9. Installed-Base and Reagent Pull-Through Strategy
13.10. Pricing and Contracting Strategy
13.11. Point-of-Care and Decentralized Market Expansion Strategy
What this section provides: This section converts market intelligence into actionable recommendations for reagent portfolio development, customer acquisition, installed-base expansion, pricing, contracting, channel strategy, investment decisions and competitive differentiation.

14. U.S. IVD Reagents Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s research boundaries, forecasting assumptions, data-use limitations, third-party information considerations and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. IVD Reagents Market: Market Definition and Scope
TABLE 3: U.S. IVD Reagents Market: Research Methodology Framework
TABLE 4: U.S. IVD Reagents Market: Key Assumptions
TABLE 5: U.S. IVD Reagents Market: Market Ecosystem Overview
TABLE 6: U.S. IVD Reagents Market: Stakeholder Analysis
TABLE 7: U.S. IVD Reagents Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. IVD Reagents Market: Analyst Viewpoint Summary
TABLE 9: U.S. IVD Reagents Market: Market Attractiveness Index
TABLE 10: U.S. IVD Reagents Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. IVD Reagents Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. IVD Reagents Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. IVD Reagents Market: Drivers; Impact Analysis
TABLE 14: U.S. IVD Reagents Market: Restraints; Impact Analysis
TABLE 15: U.S. IVD Reagents Market: Opportunities; Impact Analysis
TABLE 16: U.S. IVD Reagents Market: Challenges; Impact Analysis
TABLE 17: U.S. IVD Reagents Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. IVD Reagents Market: Clinical Laboratory Workflow Economics Matrix
TABLE 19: U.S. IVD Reagents Market: Reagent Cost-per-Reportable-Result Analysis
TABLE 20: U.S. IVD Reagents Market: Hospital and Reference Laboratory Procurement Behavior Matrix
TABLE 21: U.S. IVD Reagents Market: Analyzer Installed-Base and Reagent Pull-Through Economics
TABLE 22: U.S. IVD Reagents Market: PESTEL Analysis
TABLE 23: U.S. IVD Reagents Market: Porter’s Five Forces Analysis
TABLE 24: U.S. IVD Reagents Market: Reagent Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. IVD Reagents Market: Value Chain Analysis
TABLE 26: U.S. IVD Reagents Market: Supply Chain Analysis
TABLE 27: U.S. IVD Reagents Market: Digitalization and Clinical Laboratory Automation Impact
TABLE 28: U.S. IVD Reagents Market: Application & Innovation Landscape
TABLE 29: U.S. IVD Reagents Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. IVD Reagents Market: CLIA Testing Complexity and Compliance Landscape
TABLE 31: U.S. IVD Reagents Market: Laboratory-Developed Test Regulatory Landscape
TABLE 32: U.S. IVD Reagents Market: CMS Clinical Laboratory Reimbursement and Coverage Landscape
TABLE 33: U.S. IVD Reagents Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. IVD Reagents Market: Government Initiatives and Public Health Testing Programs
TABLE 35: U.S. IVD Reagents Market: Impact of Escalating Geopolitical and Supply Chain Tensions
TABLE 36: U.S. IVD Reagents Market: Laboratory Value Analysis and Vendor Selection Framework
TABLE 37: U.S. IVD Reagents Market: Reagent-Rental and Analyzer Placement Business Model Analysis
TABLE 38: U.S. IVD Reagents Market: Reagent Type Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Reagent Type
TABLE 40: U.S. IVD Reagents Market, by Reagent Type, 2021–2035 (US$ Billion)
TABLE 41: U.S. IVD Reagents Market: Segment Share Analysis, by Reagent Type, 2025 & 2035 (%)
TABLE 42: U.S. IVD Reagents Market: Antibodies and Antigens Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. IVD Reagents Market: Oligonucleotides, Primers and Nucleic Acid Probes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. IVD Reagents Market: Enzymes, Substrates and Diagnostic Biochemicals Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. IVD Reagents Market: Calibrators and Controls Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. IVD Reagents Market: Stains, Culture Media, Buffers and Other Specialty Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. IVD Reagents Market: Technology Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Technology
TABLE 49: U.S. IVD Reagents Market, by Technology, 2021–2035 (US$ Billion)
TABLE 50: U.S. IVD Reagents Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 51: U.S. IVD Reagents Market: Immunoassay and Immunochemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. IVD Reagents Market: Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. IVD Reagents Market: Molecular Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. IVD Reagents Market: Hematology and Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. IVD Reagents Market: Microbiology, Cytology and Other Diagnostic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. IVD Reagents Market: Application Snapshot, 2025
TABLE 57: Segment Dashboard; Definition and Scope, by Application
TABLE 58: U.S. IVD Reagents Market, by Application, 2021–2035 (US$ Billion)
TABLE 59: U.S. IVD Reagents Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 60: U.S. IVD Reagents Market: Infectious Diseases Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. IVD Reagents Market: Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. IVD Reagents Market: Diabetes, Cardiometabolic and Endocrine Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. IVD Reagents Market: Autoimmune and Inflammatory Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. IVD Reagents Market: Women’s Health, Genetic and Other Specialty Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. IVD Reagents Market: End User Snapshot, 2025
TABLE 66: Segment Dashboard; Definition and Scope, by End User
TABLE 67: U.S. IVD Reagents Market, by End User, 2021–2035 (US$ Billion)
TABLE 68: U.S. IVD Reagents Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 69: U.S. IVD Reagents Market: Hospitals and Health-System Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. IVD Reagents Market: Independent and Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. IVD Reagents Market: Physician-Office Laboratories, Urgent Care and Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. IVD Reagents Market: Decentralized, Retail and Near-Patient Testing Sites Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. IVD Reagents Market: Blood Banks, Public Health Laboratories and Specialty Institutions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. IVD Reagents Market: Procurement Channel Snapshot, 2025
TABLE 75: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 76: U.S. IVD Reagents Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 77: U.S. IVD Reagents Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 78: U.S. IVD Reagents Market: Direct Manufacturer-to-Laboratory Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. IVD Reagents Market: Integrated Delivery Network and Health-System Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. IVD Reagents Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. IVD Reagents Market: Distributor and Specialty Laboratory Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. IVD Reagents Market: Physician-Office, Point-of-Care and Decentralized Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. IVD Reagents Market: Regional Snapshot, 2025
TABLE 84: Segment Dashboard; Definition and Scope, by Region
TABLE 85: U.S. IVD Reagents Market, by Region, 2021–2035 (US$ Billion)
TABLE 86: U.S. IVD Reagents Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 87: West Region U.S. IVD Reagents Market: Regional Overview and Trends
TABLE 88: West Region U.S. IVD Reagents Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 89: West Region U.S. IVD Reagents Market, by State, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. IVD Reagents Market, by Reagent Type, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. IVD Reagents Market, by Technology, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. IVD Reagents Market, by Application, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. IVD Reagents Market, by End User, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. IVD Reagents Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 95: California IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Washington IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Arizona IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Colorado IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Oregon IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Utah IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Nevada IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Mexico IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Idaho IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Montana IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Wyoming IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Alaska IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Hawaii IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. IVD Reagents Market: Regional Overview and Trends
TABLE 109: Northeast Region U.S. IVD Reagents Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 110: Northeast Region U.S. IVD Reagents Market, by State, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. IVD Reagents Market, by Reagent Type, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. IVD Reagents Market, by Technology, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. IVD Reagents Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. IVD Reagents Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. IVD Reagents Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 116: New York IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. IVD Reagents Market: Regional Overview and Trends
TABLE 127: South Region U.S. IVD Reagents Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 128: South Region U.S. IVD Reagents Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. IVD Reagents Market, by Reagent Type, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. IVD Reagents Market, by Technology, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. IVD Reagents Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. IVD Reagents Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. IVD Reagents Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: Texas IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Florida IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Georgia IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: North Carolina IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Tennessee IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: South Carolina IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Alabama IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Mississippi IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Louisiana IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Arkansas IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Kentucky IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Oklahoma IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Virginia IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Maryland IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: West Virginia IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. IVD Reagents Market: Regional Overview and Trends
TABLE 150: Midwest Region U.S. IVD Reagents Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 151: Midwest Region U.S. IVD Reagents Market, by State, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. IVD Reagents Market, by Reagent Type, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. IVD Reagents Market, by Technology, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. IVD Reagents Market, by Application, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. IVD Reagents Market, by End User, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. IVD Reagents Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 157: Illinois IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Ohio IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Michigan IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Minnesota IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Indiana IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Wisconsin IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Missouri IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Iowa IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Kansas IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Nebraska IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: North Dakota IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: South Dakota IVD Reagents Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: U.S. IVD Reagents Market: Competitive Landscape Snapshot, 2025
TABLE 170: U.S. IVD Reagents Market: Key Company Market Share Analysis, 2025
TABLE 171: U.S. IVD Reagents Market: Company Positioning Matrix
TABLE 172: U.S. IVD Reagents Market: Reagent and Assay Portfolio Benchmarking of Key Players
TABLE 173: U.S. IVD Reagents Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 174: Roche Diagnostics: Company Profile
TABLE 175: Abbott: Company Profile
TABLE 176: Siemens Healthineers: Company Profile
TABLE 177: Beckman Coulter Diagnostics: Company Profile
TABLE 178: Cepheid: Company Profile
TABLE 179: Thermo Fisher Scientific: Company Profile
TABLE 180: bioMérieux: Company Profile
TABLE 181: Bio-Rad Laboratories: Company Profile
TABLE 182: QuidelOrtho: Company Profile
TABLE 183: Hologic: Company Profile
TABLE 184: Becton, Dickinson and Company: Company Profile
TABLE 185: QIAGEN: Company Profile
TABLE 186: DiaSorin: Company Profile
TABLE 187: Sysmex America: Company Profile
TABLE 188: Werfen: Company Profile
TABLE 189: Grifols Diagnostic Solutions: Company Profile
TABLE 190: Agilent Technologies: Company Profile
TABLE 191: Revvity: Company Profile
TABLE 192: Fujirebio Diagnostics: Company Profile
TABLE 193: Sekisui Diagnostics: Company Profile
TABLE 194: Meridian Bioscience: Company Profile
TABLE 195: Randox Laboratories: Company Profile
TABLE 196: Bio-Techne: Company Profile
TABLE 197: Illumina: Company Profile
TABLE 198: Mindray: Company Profile
TABLE 199: U.S. IVD Reagents Market: Future Market Scenario Analysis, 2026–2035
TABLE 200: U.S. IVD Reagents Market: Disruptive Technologies Impact Matrix
TABLE 201: U.S. IVD Reagents Market: Emerging Business Trends
TABLE 202: U.S. IVD Reagents Market: Business Opportunities for Startups and Existing Players
TABLE 203: U.S. IVD Reagents Market: Investment Prioritization Matrix
TABLE 204: U.S. IVD Reagents Market: High-Growth Reagent Opportunity Mapping
TABLE 205: U.S. IVD Reagents Market: Technology Adoption Roadmap, 2026–2035
TABLE 206: U.S. IVD Reagents Market: Strategic Recommendations for IVD Reagent and Diagnostic Manufacturers
TABLE 207: U.S. IVD Reagents Market: Strategic Recommendations for Hospitals, Health Systems and Clinical Laboratories
TABLE 208: U.S. IVD Reagents Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 209: U.S. IVD Reagents Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 210: U.S. IVD Reagents Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 211: U.S. IVD Reagents Market: Strategic Recommendations for New Entrants and Diagnostic Startups
TABLE 212: U.S. IVD Reagents Market: Go-to-Market Strategy Considerations
TABLE 213: U.S. IVD Reagents Market: Assay Menu and Portfolio Expansion Guidance
TABLE 214: U.S. IVD Reagents Market: Installed-Base and Reagent Pull-Through Strategy
TABLE 215: U.S. IVD Reagents Market: Pricing and Contracting Strategy
TABLE 216: U.S. IVD Reagents Market: Point-of-Care and Decentralized Market Expansion Strategy
TABLE 217: U.S. IVD Reagents Market: Scope Limitation
TABLE 218: U.S. IVD Reagents Market: Data Use Limitation
TABLE 219: U.S. IVD Reagents Market: Forecasting Limitation
TABLE 220: U.S. IVD Reagents Market: Legal Disclaimer
TABLE 221: U.S. IVD Reagents Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. IVD Reagents Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Laboratory Workflow Economics Framework
FIGURE 11: Reagent Cost-per-Reportable-Result Framework
FIGURE 12: Hospital and Reference Laboratory Procurement Decision Framework
FIGURE 13: Analyzer Installed-Base and Reagent Pull-Through Economics Framework
FIGURE 14: U.S. IVD Reagents Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. IVD Reagents Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. IVD Reagents Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Reagent Type Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Reagent Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Antibodies and Antigens Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Oligonucleotides, Primers and Nucleic Acid Probes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Enzymes, Substrates and Diagnostic Biochemicals Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Calibrators and Controls Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Stains, Culture Media, Buffers and Other Specialty Reagents Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Immunoassay and Immunochemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Molecular Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Hematology and Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Microbiology, Cytology and Other Diagnostic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Infectious Diseases Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Oncology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Diabetes, Cardiometabolic and Endocrine Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Autoimmune and Inflammatory Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Women’s Health, Genetic and Other Specialty Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Hospitals and Health-System Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Independent and Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Physician-Office Laboratories, Urgent Care and Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Decentralized, Retail and Near-Patient Testing Sites Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Blood Banks, Public Health Laboratories and Specialty Institutions Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Direct Manufacturer-to-Laboratory Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Integrated Delivery Network and Health-System Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Distributor and Specialty Laboratory Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Physician-Office, Point-of-Care and Decentralized Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: West Region U.S. IVD Reagents Market Share and Leading Players, 2025
FIGURE 55: West Region Market Share Analysis by State, 2025
FIGURE 56: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: California IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Washington IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Arizona IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Colorado IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Oregon IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Utah IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Nevada IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: New Mexico IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Idaho IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Montana IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Wyoming IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Alaska IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Hawaii IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Northeast Region U.S. IVD Reagents Market Share and Leading Players, 2025
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Massachusetts IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Jersey IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Pennsylvania IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Connecticut IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Maine IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Vermont IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Hampshire IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Rhode Island IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Delaware IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: South Region U.S. IVD Reagents Market Share and Leading Players, 2025
FIGURE 84: South Region Market Share Analysis by State, 2025
FIGURE 85: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Texas IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Florida IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Georgia IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: North Carolina IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Tennessee IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Carolina IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Alabama IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Mississippi IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Louisiana IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Arkansas IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Kentucky IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Oklahoma IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Virginia IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Maryland IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: West Virginia IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Midwest Region U.S. IVD Reagents Market Share and Leading Players, 2025
FIGURE 102: Midwest Region Market Share Analysis by State, 2025
FIGURE 103: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Illinois IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Ohio IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Michigan IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Minnesota IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Indiana IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Wisconsin IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Missouri IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Iowa IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Kansas IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Nebraska IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: North Dakota IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: South Dakota IVD Reagents Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 117: Company Positioning Matrix
FIGURE 118: Key Player Reagent and Assay Portfolio Benchmarking
FIGURE 119: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 120: IVD Reagent Innovation Roadmap
FIGURE 121: Multiplex and Syndromic Molecular Assay Adoption Roadmap
FIGURE 122: Point-of-Care PCR and Decentralized Testing Opportunity Map
FIGURE 123: Oncology Biomarkers and Companion Diagnostics Growth Roadmap
FIGURE 124: Future Market Scenario Analysis, 2026–2035
FIGURE 125: Disruptive Technologies Impact Matrix
FIGURE 126: Emerging Business Trends Matrix
FIGURE 127: Investment Prioritization Matrix
FIGURE 128: High-Growth Reagent Opportunity Map
FIGURE 129: Technology Adoption Roadmap, 2026–2035
FIGURE 130: Strategic Growth Roadmap for U.S. IVD Reagent Companies
FIGURE 131: Go-to-Market Strategy Framework
FIGURE 132: Assay Menu and Portfolio Expansion Framework
FIGURE 133: Installed-Base and Reagent Pull-Through Strategy Framework
FIGURE 134: Report Scope and Disclaimer Framework